Kilitch Drugs Q1 FY26: Stable Revenue, Margin Pressure, Export Focus

$KILITCH 📊 Q1 FY26 Financial Snapshot Net Profit: ₹29M vs ₹30M (YoY slight decline). Revenue: ₹449M vs ₹431M (YoY +4%). EBITDA: ₹29M vs ₹33M (YoY -12%). EBITDA Margin: 6.53% vs 7.56% (YoY decline due to cost pressures). 📌 Fundamentals & Ratios Debt-to-Equity: ~0.2, very low leverage, strong balance sheet. P/E Ratio: ~16–18, fair valuation for mid-cap pharma. ROE: ~10–11%, moderate efficiency. EBITDA Margin: 6.53%, showing margin pressure. Dividend Yield: ~0.5%, modest payout. 💊 Key Projects & Business Drivers Injectables & Formulations: Focus on niche pharma segments. Export Growth: Expanding presence in Africa and emerging markets. Contract Manufacturing: Leveraging partnerships for scale. R&D Initiatives: Developing new formulations in generics. Capacity Expansion: Incremental investments in manufacturing facilities. ⚠️ Risks & Watchpoints Margin Compression: Rising input costs impacting profitability. Competition: Intense rivalry in generics and formulations. Regulatory Risks: Compliance with global pharma standards. Execution Risks: Scaling exports and manufacturing efficiently. Demand Cyclicality: Dependent on healthcare spending trends.